© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
May 27, 2022
Analysis is one of the largest-ever series of outcomes for patients with renal masses in a solitary kidney.
May 02, 2022
The study specifically examined this precision medicine pathway in the context of frontline treatment selection between nivolumab with or without ipilimumab and a VEGFR tyrosine kinase inhibitor.
April 22, 2022
Combination therapy with the novel TKI sitravatinib and the anti–PD-1 immune checkpoint inhibitor nivolumab showed promising efficacy and safety in patients with clear cell renal cell carcinoma and progression after antiangiogenic therapy.
Surgical approach and ischemia time are among key topics.
April 06, 2022
"Cryotherapy was the first energy source that we were able to ablate tissues with in either the kidney or prostate and understand what that ablation would do," says J. Stephen Jones, MD, FACS.
March 21, 2022
“The question of who is a candidate for active surveillance is hard to answer because this is a bedside, gut decision," says Primo Nery Lara, Jr, MD.
March 18, 2022
Gennady Bratslavsky, MD highlighted studies examining (neo)adjuvant immunotherapy in the setting of nephrectomy for locally advanced disease, such as the PROSPER (NCT03055013) and KEYNOTE-564 (NCT03142334) trials.
March 16, 2022
“One of the reasons I so enjoy this conference is the multidisciplinary nature,” says Peter A. Humphrey, MD, PhD.
March 15, 2022
“There are, indeed, numerous paths that we are trying to tackle from different angles,” says Gennady Bratslavsky, MD.